19 patents
Utility
Predictive Outcome Profiling for Use of an ANTI-SEMAPHORIN-4D Binding Molecule to Treat Neurodegenerative Disorders
30 Mar 23
Provided herein are methods for selecting subjects having a neurodegenerative disorder for treatment with an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D), method for predicting the treatment outcome of subjects having a neurodegenerative disorder that are treated with an isolated binding molecule which specifically binds to SEMA4D and methods for treating subjects having a neurodegenerative disorder with an isolated binding molecule which specifically binds to SEMA4D.
Maurice Zauderer, Elizabeth Evans, Terrence Fisher
Filed: 23 Sep 22
Utility
Human Anti-semaphorin 4D Antibody
10 Nov 22
Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
Ernest S. SMITH, Angelica CORNELISON, Maria SCRIVENS, Mark PARIS, Maurice ZAUDERER
Filed: 19 Jul 22
Utility
ANTI-CD100 Antibodies and Methods for Using the Same
16 Jun 22
Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers.
Ernest S. Smith, Terrence Lee Fisher
Filed: 31 Jan 22
Utility
Use of SEMAPHORIN-4D Binding Molecules for the Treatment of Rett Syndrome
30 Dec 21
Provided herein are methods for alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).
Yilin Mao, Wendy Gold, Elizabeth E. Evans, Maurice Zauderer
Filed: 21 Jun 21
Utility
Use of CXCL13 Binding Molecules to Promote Peripheral Nerve Regeneration
16 Dec 21
Provided herein are methods for promoting axonal regeneration of sensory neurons and functional recovery of neurons following peripheral nerve injury in a subject experiencing aging-dependent nerve regenerative decline, the method comprising administering to a subject in need thereof an effective amount of an isolated binding molecule which specifically binds to CXCL13.
Simone DiGiovanni, Luming Zhou
Filed: 8 Jun 21
Utility
Integral Membrane Protein Display on Poxvirus Extracellular Enveloped Virions
11 Nov 21
This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation on poxvirus extracellular virions and methods for screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target IMP of interest.
Ernest S. Smith, Maria G.M. Scrivens, Loretta Mueller, Shuying Shi, Leslie A. Balch
Filed: 5 May 21
Utility
Use of SEMAPHORIN-4D Inhibitory Molecules with an Immune Modulating Therapy to Inhibit Tumor Growth and Metastases
21 Oct 21
Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
Elizabeth E. Evans, Ernest S. Smith, Maurice Zauderer
Filed: 29 Jun 21
Utility
ANTI-CCR8 Antibodies and Uses Thereof
5 Aug 21
The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same.
Pamela M. HOLLAND, Andrew LAKE, Austin DULAK, Ernest SMITH, Maria SCRIVENS, Carrie HARVEY, Renee KIRK, Leslie BALCH, Sonia G. DAS, Christopher Converse WELLS
Filed: 6 Jan 21
Utility
Treatment of Cancer with a SEMAPHORIN-4D Antibody In Combination with an Epigenetic Modulating Agent
17 Jun 21
This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof.
Elizabeth EVANS, Ernest SMITH, Maurice ZAUDERER
Filed: 14 Mar 18
Utility
ANTI-CXCL13 Antibodies and Methods of Using the Same
25 Mar 21
Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers.
Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
Filed: 24 Sep 20
Utility
Combined Inhibition of SEMAPHORIN-4D and Tgf-beta and Compositions Therefor
4 Feb 21
Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of plexin-B1, plexin-B2, and/or CD72-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of antibody or antigen-binding fragment thereof that inhibits TGFβ, and, optionally, at least one other immune modulating therapy.
Elizabeth E. Evans, Holm Bussler
Filed: 30 Jul 20
Utility
Human Anti-semaphorin 4D Antibody
4 Feb 21
Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
Ernest S. SMITH, Angelica CORNELISON, Maria G.M. SCRIVENS, Mark PARIS, Maurice ZAUDERER
Filed: 4 May 18
Utility
Combination Therapy with SEMAPHORIN-4D Blockade (SEMA4D) and DC1 Therapy
23 Dec 20
Disclosed are compositions and methods comprising the administration of pulsed dendritic cells and an immunoregulator molecule inhibitor for the treatment of cancer.
Brian Czerniecki, Krithika N. Kodumudi, Elizabeth Evans
Filed: 18 Jun 20
Utility
SEMAPHORIN-4D Antagonists for Use In Cancer Therapy
7 Oct 20
The disclosure relates to methods for treating cancer comprising determining certain patient biomarker levels prior to treatment.
Terrence Lee Fisher, Elizabeth Evans, Maurice Zauderer
Filed: 26 Mar 20
Utility
Methods for Producing Polynucleotide Libraries In Vaccinia Virus/eukaryotic Cells
23 Sep 20
This disclosure provides an improved method of constructing a library of polynucleotides of interest in a poxvirus, vaccinia virus vector system, where the polynucleotides of interest encode polypeptides of interest.
Ernest SMITH, Shuying SHI
Filed: 27 Apr 20
Utility
Integral Membrane Protien Display on Poxvirus Extracellular Enveloped Virions
8 Jul 20
This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
Ernest S. Smith, Mark Paris, Maria G.M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
Filed: 25 Dec 19
Utility
Early Detection of Glial Cell Activation In Neurodegenerative or Neuroinflammatory Diseases
18 Dec 19
The disclosure provides a method for determining the efficacy of treatment with a SEMA4D antagonist, e.g., a SEMA4D antagonist antibody in the treatment of a neuroinflammatory or neurodegenerative disease, disorder, or injury, where the method provides differential measurement of glucose uptake in the brain, e.g., by FDG-PET imaging.
Maurice ZAUDERER
Filed: 19 Feb 18
Utility
Use of SEMAPHORIN-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability
27 Nov 19
Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.
Ernest S. Smith, Maurice Zauderer
Filed: 5 Jun 19
Utility
Use of SEMAPHORIN-4D Binding Molecules for Treating Neurodegenerative Disorders
23 Oct 19
Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
Filed: 1 Jul 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first